上海医药工业研究院近十年创新药物研究进展

The Progress of the Research on New Drug During the Past Ten Years in SIPI

近10年来上海医药工业研究院(简称"我院")在创新药物研究领域围绕中枢神经系统疾病、感染性疾病、恶性肿瘤、心脑血管系统疾病等开展原创性新药研发,取得了一定成绩。本文梳理了我院近10年在国内外期刊公开发表的部分研究论文,综述了上述领域的原创性新药研究概况。其中抗脑中风I类新药"盐酸非那嗪奈注射液"于2006年获得临床批件,此外在抗抑郁症、抗精神分裂、中枢镇痛、抗感染、抗恶性肿瘤、降血脂和糖尿病等新药领域方面,亦建立丰富的活性化合物库,为进一步发现候选新药奠定了基础。

Based on the articles published by the scientists from Shanghai Institute of Pharmaceutical Industry （SIPI） during the past ten years, this paper summarizes the progress of the new drug research in SIPI on the fields of central nervous system （CNS） diseases, infectious diseases, cancer, cardiovascular and cerebrovascular diseases. Among them, fenazinel dihydrochloride was developed into clinical trials as a novel neuroprotective agent in 2006. Meanwhile, the researchers at the SIPI have identified a number of candidate drugs in the field of CNS, anti-infective, molecular- targeted anti-tumor and cardiovascular.